Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab: An Observational Health Data Sciences and Informatics Network Study
Cindy X. Cai, Akihiko Nishimura, Mary G. Bowring, Erik Westlund, Diep Tran, Jia H. Ng, Paul Nagy, Michael Cook, Jody Ann McLeggon, Scott L. DuVall, Michael E. Matheny, Asieh Golozar, Anna Ostropolets, Evan Minty, Priya Desai, Fan Bu, Brian Toy, Michelle Hribar, Thomas Falconer, Linying ZhangLaurence Lawrence-Archer, Michael V. Boland, Kerry Goetz, Nathan Hall, Azza Shoaibi, Jenna Reps, Anthony G. Sena, Clair Blacketer, Joel Swerdel, Kenar D. Jhaveri, Edward Lee, Zachary Gilbert, Scott L. Zeger, Deidra C. Crews, Marc A. Suchard, George Hripcsak, Patrick B. Ryan
Dive into the research topics of 'Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab: An Observational Health Data Sciences and Informatics Network Study'. Together they form a unique fingerprint.